1460 Broadway Street
About Ovid Therapeutics
40 articles with Ovid Therapeutics
9/16/2019Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.
Ovid Therapeutics Announces First Patient Randomized in Pivotal Phase 3 NEPTUNE Trial of OV101 for the Treatment of Angelman Syndrome
OV101 May Become the First Medicine for Individuals with Angelman Syndrome; Topline Results Expected in Mid-2020
In Wake of Terminations, Pharma Leaders Decry Actions That Will Limit Collaborations with Foreign...
8/23/2019Leaders from across the pharmaceutical industry are decrying negative actions taken by government agencies and universities against Chinese researchers in the United States.
Ovid Therapeutics Initiates Pivotal Phase 3 Clinical Trial in Angelman Syndrome; Multiple Data Readouts Across Rare Neurological Disease Pipeline Expected in 2H 2019 and Early 2020
Ovid Therapeutics Inc. (NASDAQ: OVID), today announced that following a Type C Meeting with the U.S. Food and Drug Administration(FDA), it has initiated the pivotal Phase 3 NEPTUNE trial with OV101, a novel delta (δ)-selective GABAA receptor agonist, in Angelman syndrome
Ovid Therapeutics Inc., a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, will present data on safety, tolerability, exploratory and secondary outcomes from the Phase 1b/2a clinical trial of OV935/TAK-935 in adult patients with developmental and epileptic encephalopathies.
Ovid CEO Jeremy Levin Puts the Patient First as He Seeks to Revolutionize Drug Development in Neu...
1/28/2019As the chief executive officer of Ovid Therapeutics, Jeremy Levin has a lot on his plate. But, there is one thing always in the forefront of Levin’s mind – the patients his company can serve.
Ovid’s Angelman Syndrome Therapy Hits Prespecified Endpoint Phase II Trial, Shares Drop Significa...
8/6/2018Ovid Therapeutics is shouting good news from the rooftops regarding its mid-stage Angelman Syndrome study, but investors are not convinced.
Pharmaceutical execs who leave their positions with big pharmaceutical companies, unless opting to retire for good, often move to leadership positions at other big companies. There are other choices.
Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation by U.S. FDA for Treatment of Lennox-Gastaut Syndrome
Takeda and Ovid formed a global collaboration in January 2017 to develop and commercialize TAK-935/OV935 for the treatment of developmental and epileptic encephalopathies
Ovid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Angelman Syndrome
Upon successful completion of a Phase 1 pharmacokinetic (PK) and safety study showing that OV101 has a similar PK profile in adolescents as in adults, Ovid recently amended the STARS protocol to include patients aged 13 years and older.
Ovid Therapeutics Announces TAK-935/OV935 Has Received Orphan Drug Designation From U.S. FDA for Treatment of Dravet Syndrome
Takeda and Ovid formed a global collaboration to develop and commercialize TAK-935/OV935 for the treatment of developmental and epileptic encephalopathies in January 2017.
Ovid Therapeutics Presents New Data Demonstrating Potential of TAK-935/OV935 as a Novel Treatment for Developmental and Epileptic Encephalopathies at the American Epilepsy Society (AES) Annual Meeting
The data were presented at the American Epilepsy Society 71st Annual Meeting, taking place December 1-5, 2017, at the Walter E. Washington Convention Center in Washington, D.C.
Ovid Therapeutics Announces OV101 Shows Comparable PK Profile in Phase 1 Study of Adolescent Patients and Amends Phase II STARS Clinical Trial Protocol to Include Adolescents
The Company will now include adolescent patients aged 13 years and older in the Phase 2 STARS trial.
As of September 30, 2017, cash and cash equivalents totaled $96.0 million.
Ovid Therapeutics Announces Positive Preclinical OV101 Data Demonstrating Behavioral Improvements in Fragile X Syndrome Model
Ovid announced new positive preclinical data on OV101 that shows normalization of behavioral abnormalities that resemble those seen in people with Fragile X syndrome.
Ovid Receives Orphan Drug Designation From The U.S. FDA For OV101 For Treatment Of Fragile X Syndrome
Ovid To Present Preclinical Data Demonstrating OV101 Normalizes Behavioral Abnormalities At The 18th International Fragile X And Related Neurodevelopmental Disorders Workshop
Ovid Therapeutics Announces First Patient Randomized In Phase Ib/IIa Clinical Trial Of TAK-935/OV935 In Adults With Rare Epilepsies